Organon
Manufacturing · New Jersey, United States · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
30 Hudson St Fl 33, Jersey City, New Jer...Phone Number
(551) 430-6000Website
www.organon.comRevenue
$6.2 BillionStock Symbol
OGNIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
12
13
1
2
2
2
About Organon
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage each of its core therapeutic fields.Explore more
Organon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Organon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Organon recently announced quarterly report
Check out if Organon is spiking on competitors!
Funding: Get notified immidiatlly once Organon has new funding data
Check if Organon has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Organon launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Organon had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Organon
Organon, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Organon
Compare insights from companies similar to Organon, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Organon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Organon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Organon.
Organon Tech Stack
A closer look at the technologies used by Organon
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Organon News & Media
SCPI set for delisting after 13 years under suspension - IDNFinancials
Suspended since 2013, SCPI to exit the exchange and set tender offer price of IDR 100,000 per share.BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Veris Residential, Inc. (NYSE – VRE), XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX)
BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
SHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.[1] "As the first, and currently the only, pertuzumab biosimilar in Europe, the EC's approval of POHERDY marks an important
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Organon
Sign Up For FreeTo access detailed company insights
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage each of its core therapeutic fields.... Read More
